1118567-05-7

Basic information

• Product Name: EGT1442
• Synonyms: EGT1442;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol;Bexagliflozin
• CAS NO: 1118567-05-7
• Molecular Formula: C₂₄H₂₉ClO₇
• Molecular Weight: 464.93586
• Mol File: 1118567-05-7.mol

Chemical Properties

• Boiling Point: 671.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.41
• PKA: 13.23±0.70(Predicted)
• CAS DataBase Reference: EGT1442(CAS DataBase Reference)
• NIST Chemistry Reference: EGT1442(1118567-05-7)
• EPA Substance Registry System: EGT1442(1118567-05-7)

Safety Data

• Hazardous Substances Data: 1118567-05-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
EGT1442 is used as an SGLT2 inhibitor for the management of type 2 diabetes. It helps in reducing blood glucose and HbA(1c) levels in a concentration-dependent manner, providing a potential therapeutic option for patients with this condition.
Used in Research and Development:
In addition to its pharmaceutical applications, EGT1442 can be utilized in research and development for studying the role of SGLT2 in glucose regulation and the development of type 2 diabetes. Its potent and selective inhibition of SGLT2 makes it a valuable tool for understanding the underlying mechanisms and potential treatment strategies for this metabolic disorder.

Upstream product

• 90-80-2 D-Glucono-1,5-lactone 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 1459754-30-3 (3R,4S,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 20117-44-6 2-(cyclopropyloxy)ethan-1-ol 
• 461432-24-6 (3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1118566-45-2 (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 18742-02-4 2-bromo-2-(2-ethyl)dioxolane 
• 1118566-69-0 2-(4-(5-bromo-2-chlorobenzyl)phenoxy)ethyl 4-methylbenzenesulfonate 
• 1118566-50-9 2-(4-(5-bromo-2-chlorobenzyl)phenoxy)ethanol 
• 1118567-45-5 4-bromo-1-chloro-2-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]benzene 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 

Relevant articles and documents

An efficient method for synthesis of bexagliflozin and its carbon-13 labeled analogue

A convenient method for highly diastereoselective synthesis of bexagliflozin 7a and its carbon-13 labeled analogue 7b was developed. The main feature is the stereoselective reduction of 16 catalyzed by BF3·OEt2. Furthermore, the cocrystallization skill was firstly used for the purification of bexagliflozin and its analogue. The carbon-13 labeled bexagliflozin 7b was firstly prepared in five steps and in 57% overall chemical yield starting from the commercially available D-gluconolactone-[13C6].

PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter (SGLT) and synthetic intermediates useful for preparing such compounds.

C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

A series of C-aryl glucosides with various substituents at the 4′-position of the distal aryl ring have been synthesized and evaluated for inhibition of hSGLT1 and hSGLT2. Introduction of alkyl or alkoxy substituents at the 4′-position was found to improve SGLT2 potency, whereas introduction of a hydrophilic group at this position was deleterious. Compounds with alkoxy-, cycloalkoxy- or cycloalkenyloxy-ethoxy scaffolds exhibited good inhibitory activity and high selectivity toward SGLT2. Selected compounds were investigated for in vivo efficacy.

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition are also disclosed.

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods for preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition are also disclosed.

PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS

Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.

BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.